Omeros jumps on surprise quarterly profit

** Shares of drugmaker Omeros (OMER.O) rose 17% to $16.05 in premarket trading.

** The company reported second-quarter profit of 15 cents per share versus analysts' average estimate of a loss of 27 cents per share, according to LSEG data.

** Omeros' second-quarter revenue of $28.5 million beat analysts' expectation of $12.7 million on strong sales of its drug Yartemlea.

** Yartemlea is used to treat a rare but severe medical complication where blood clots form in the small blood vessels, usually after a bone marrow or stem cell transplant.

** Up to the last close, the stock was down 20.2% year to date.